Moderate to severe vasomotor symptoms associated with estrogen deficiency.
Prevention and management of osteoporosis associated with estrogen deficiency. When prescribing solely for the prevention of post-menopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered appropriate. When prescribing solely for the management of post-menopausal osteoporosis, non-estrogen medications should be first considered.
Atrophic vaginitis and atrophic urethritis. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.
ERT and HRT should not be initiated or continued to prevent coronary heart disease (see also Cardiovascular risk and DEMENTIA).
The benefits and risks of ERT and HRT must always be carefully weighed, including consideration of the emergence of risks as therapy continues (see SPECIAL WARNINGS under Precautions). Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. In the absence of comparable data, the risks of HRT should be assumed to be similar to all estrogens and estrogen/progestin combinations.